Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
STN1013900 with or without latanoprost or timolol in open-angle glaucoma or ocular hypertension
jRCT2031210125Completed
- Sponsor
- Santen Pharmaceutical
- Start
- Jun 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised, open-label trial of netarsudil in open-angle glaucoma (OAG), normal tension glaucoma (NTG), pseudoexfoliation glaucoma (PXG) and 2 more (4 arms), sponsored by Santen Pharmaceutical. Primary endpoint: Mean diurnal intraocular pressure at each visit. Started Jun 2021; status: completed.
02
Drugs
netarsudil
03
Conditions
open-angle glaucoma (OAG)normal tension glaucoma (NTG)pseudoexfoliation glaucoma (PXG)pigmentary glaucoma (PG)ocular hypertension
Beyond the preview
Go deeper on jRCT2031210125.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031210125.